Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Oral anticoagulants. New oral anticoagulants for atrial fibrillation: the factor Xa inhibitors rivaroxaban and apixaban.

Oral anticoagulants. New oral anticoagulants for atrial fibrillation: the factor Xa inhibitors rivaroxaban and apixaban. Rev Cardiovasc Med. 2012; 13(1):e46-8.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.